Credit Suisse’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $7.36M | Buy |
89,793
+1,505
| +2% | +$123K | 0.01% | 1068 |
|
|
2023
Q4 | $1.64M | Sell |
88,288
-7,526
| -8% | -$140K | ﹤0.01% | 2008 |
|
|
2023
Q3 | $1.06M | Sell |
95,814
-17,610
| -16% | -$195K | ﹤0.01% | 2256 |
|
|
2023
Q2 | $1.84M | Buy |
113,424
+59,847
| +112% | +$970K | ﹤0.01% | 1954 |
|
|
2023
Q1 | $892K | Buy |
+53,577
| New | +$892K | ﹤0.01% | 2385 |
|
|
2022
Q3 | – | Sell |
-36
| Closed | – | – | 4299 |
|
|
2022
Q2 | $0 | Sell |
36
-49,098
| -100% | – | ﹤0.01% | 4330 |
|
|
2022
Q1 | $148K | Sell |
49,134
-1,228
| -2% | -$3.7K | ﹤0.01% | 3421 |
|
|
2021
Q4 | $231K | Buy |
50,362
+5,992
| +14% | +$27.5K | ﹤0.01% | 3397 |
|
|
2021
Q3 | $279K | Buy |
44,370
+4,783
| +12% | +$30.1K | ﹤0.01% | 3277 |
|
|
2021
Q2 | $237K | Sell |
39,587
-25,566
| -39% | -$153K | ﹤0.01% | 3370 |
|
|
2021
Q1 | $413K | Sell |
65,153
-85,770
| -57% | -$544K | ﹤0.01% | 3047 |
|
|
2020
Q4 | $849K | Sell |
150,923
-66,109
| -30% | -$372K | ﹤0.01% | 2665 |
|
|
2020
Q3 | $1.26M | Buy |
217,032
+29,123
| +15% | +$169K | ﹤0.01% | 2111 |
|
|
2020
Q2 | $1.35M | Buy |
187,909
+62,690
| +50% | +$452K | ﹤0.01% | 2131 |
|
|
2020
Q1 | $585K | Sell |
125,219
-14,477
| -10% | -$67.6K | ﹤0.01% | 2434 |
|
|
2019
Q4 | $1.12M | Buy |
139,696
+100,356
| +255% | +$805K | ﹤0.01% | 2434 |
|
|
2019
Q3 | $270K | Buy |
39,340
+4,869
| +14% | +$33.4K | ﹤0.01% | 3080 |
|
|
2019
Q2 | $286K | Sell |
34,471
-3,554
| -9% | -$29.5K | ﹤0.01% | 3065 |
|
|
2019
Q1 | $378K | Buy |
38,025
+7,660
| +25% | +$76.1K | ﹤0.01% | 2914 |
|
|
2018
Q4 | $233K | Buy |
+30,365
| New | +$233K | ﹤0.01% | 3087 |
|
|
2018
Q3 | – | Sell |
-86,488
| Closed | -$821K | – | 3428 |
|
|
2018
Q2 | $821K | Buy |
+86,488
| New | +$821K | ﹤0.01% | 2712 |
|